{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T02:04:28Z","timestamp":1792375468330,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s00415-015-7740-5","type":"journal-article","created":{"date-parts":[[2015,4,30]],"date-time":"2015-04-30T05:03:47Z","timestamp":1430370227000},"page":"1646-1654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["25-Hydroxyvitamin D levels in acute monosymptomatic optic neuritis: relation to clinical severity, paraclinical findings and risk of multiple sclerosis"],"prefix":"10.1007","volume":"262","author":[{"given":"Gorm","family":"Pihl-Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette Lautrup","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,1]]},"reference":[{"key":"7740_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1586\/14737175.2013.865866","volume":"13","author":"A Ascherio","year":"2013","unstructured":"Ascherio A (2013) Environmental factors in multiple sclerosis. Expert Rev Neurother 13:3\u20139","journal-title":"Expert Rev Neurother"},{"key":"7740_CR2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jns.2011.07.033","volume":"311","author":"J Smolders","year":"2011","unstructured":"Smolders J, Moen SM, Damoiseaux J, Huitinga I, Holmoy T (2011) Vitamin D in the healthy and inflamed central nervous system: access and function. J Neurol Sci 311:37\u201343","journal-title":"J Neurol Sci"},{"key":"7740_CR3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0003-9861(02)00580-5","volume":"408","author":"TF Meehan","year":"2002","unstructured":"Meehan TF, DeLuca HF (2002) The vitamin D receptor is necessary for 1 alpha, 25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch Biochem Biophys 408:200\u2013204","journal-title":"Arch Biochem Biophys"},{"key":"7740_CR4","doi-asserted-by":"crossref","first-page":"7861","DOI":"10.1073\/pnas.93.15.7861","volume":"93","author":"MT Cantorna","year":"1996","unstructured":"Cantorna MT, Hayes CE, DeLuca HF (1996) 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 93:7861\u20137864","journal-title":"Proc Natl Acad Sci USA"},{"key":"7740_CR5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1874364101206010065","volume":"6","author":"H Hoorbakht","year":"2012","unstructured":"Hoorbakht H, Bagherkashi F (2012) Optic neuritis, its differential diagnosis and management. Open Ophthalmol J 6:65\u201372","journal-title":"Open Ophthalmol J"},{"key":"7740_CR6","first-page":"727","volume":"65","author":"Optic Neuritis Study Group","year":"2008","unstructured":"Optic Neuritis Study Group (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65:727\u2013732","journal-title":"Arch Neurol"},{"key":"7740_CR7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00415-005-0655-9","volume":"252","author":"P Nilsson","year":"2005","unstructured":"Nilsson P, Larsson EM, Maly-Sundgren P, Perfekt R, Sandberg-Wollheim M (2005) Predicting the outcome of optic neuritis: evaluation of risk factors after 30\u00a0years of follow-up. J Neurol 252:396\u2013402","journal-title":"J Neurol"},{"key":"7740_CR8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jocn.2013.06.013","volume":"21","author":"IB Marques","year":"2014","unstructured":"Marques IB, Matias F, Silva ED, Cunha L, Sousa L (2014) Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI. J Clin Neurosci 21:583\u2013586","journal-title":"J Clin Neurosci"},{"key":"7740_CR9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ana.23591","volume":"72","author":"EM Mowry","year":"2012","unstructured":"Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, Gourraud PA, Brenneman D, Owen MC, Qualley P, Bucci M, Hauser SL, Pelletier D (2012) Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 72:234\u2013240","journal-title":"Ann Neurol"},{"key":"7740_CR10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ana.22043","volume":"68","author":"S Simpson Jr","year":"2010","unstructured":"Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, Dwyer T, Gies P, van der Mei I (2010) Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 68:193\u2013203","journal-title":"Ann Neurol"},{"key":"7740_CR11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1212\/WNL.0b013e31825fdec7","volume":"79","author":"TF Runia","year":"2012","unstructured":"Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ (2012) Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 79:261\u2013266","journal-title":"Neurology"},{"key":"7740_CR12","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1212\/WNL.0000000000000524","volume":"82","author":"MT Malik","year":"2014","unstructured":"Malik MT, Healy BC, Benson LA, Kivisakk P, Musallam A, Weiner HL, Chitnis T (2014) Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. Neurology 82:2173\u20132179","journal-title":"Neurology"},{"key":"7740_CR13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1212\/01.WNL.0000101723.79681.38","volume":"62","author":"KL Munger","year":"2004","unstructured":"Munger KL, Zhang SM, O\u2019Reilly E, Hernan MA, Olek MJ, Willett WC, Ascherio A (2004) Vitamin D intake and incidence of multiple sclerosis. Neurology 62:60\u201365","journal-title":"Neurology"},{"key":"7740_CR14","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1212\/WNL.0b013e3182343274","volume":"77","author":"MS Stein","year":"2011","unstructured":"Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, Kilpatrick TJ (2011) A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 77:1611\u20131618","journal-title":"Neurology"},{"key":"7740_CR15","first-page":"452541","volume":"2012","author":"V Shaygannejad","year":"2012","unstructured":"Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H (2012) Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int 2012:452541","journal-title":"Mult Scler Int"},{"key":"7740_CR16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3109\/08820139.2011.573041","volume":"40","author":"G Mosayebi","year":"2011","unstructured":"Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P (2011) Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest 40:627\u2013639","journal-title":"Immunol Invest"},{"key":"7740_CR17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/jnnp-2011-301876","volume":"83","author":"M Soilu-Hanninen","year":"2012","unstructured":"Soilu-Hanninen M, Aivo J, Lindstrom BM, Elovaara I, Sumelahti ML, Farkkila M, Tienari P, Atula S, Sarasoja T, Herrala L, Keskinarkaus I, Kruger J, Kallio T, Rocca MA, Filippi M (2012) A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 83:565\u2013571","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7740_CR18","first-page":"802796","volume":"2012","author":"J Aivo","year":"2012","unstructured":"Aivo J, Lindsrom BM, Soilu-Hanninen M (2012) A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Mult Scler Int 2012:802796","journal-title":"Mult Scler Int"},{"key":"7740_CR19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamaneurol.2013.5993","volume":"71","author":"A Ascherio","year":"2014","unstructured":"Ascherio A, Munger KL, White R, Kochert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalban X, Edan G, Barkhof F, Pleimes D, Radu EW, Sandbrink R, Kappos L, Pohl C (2014) Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 71:306\u2013314","journal-title":"JAMA Neurol"},{"key":"7740_CR20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1352458513494959","volume":"20","author":"V Martinelli","year":"2014","unstructured":"Martinelli V, Dalla Costa G, Colombo B, Dalla Libera D, Rubinacci A, Filippi M, Furlan R, Comi G (2014) Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 20:147\u2013155","journal-title":"Mult Scler"},{"key":"7740_CR21","first-page":"313","volume":"3","author":"M Etemadifar","year":"2012","unstructured":"Etemadifar M, Abtahi SH, Razmjoo H, Abtahi MA, Dehghani A, Salari M, Maghzi AH, Akbari M (2012) 25-Hydroxyvitamin D concentrations in patients with optic neuritis as a clinically isolated syndrome and healthy controls. Int J Prev Med 3:313\u2013317","journal-title":"Int J Prev Med"},{"key":"7740_CR22","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ana.21972","volume":"67","author":"EM Mowry","year":"2010","unstructured":"Mowry EM, Krupp LB, Milazzo M, Chabas D, Strober JB, Belman AL, McDonald JC, Oksenberg JR, Bacchetti P, Waubant E (2010) Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 67:618\u2013624","journal-title":"Ann Neurol"},{"key":"7740_CR23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s13760-012-0166-2","volume":"113","author":"H Derakhshandi","year":"2013","unstructured":"Derakhshandi H, Etemadifar M, Feizi A, Abtahi SH, Minagar A, Abtahi MA, Abtahi ZA, Dehghani A, Sajjadi S, Tabrizi N (2013) Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial. Acta Neurol Belg 113:257\u2013263","journal-title":"Acta Neurol Belg"},{"key":"7740_CR24","unstructured":"Hupperts R (2014) Supplementation of VigantOL\u00ae oil versus placebo as add-on in patients with relapsing remitting multiple sclerosis receiving Rebif\u00ae treatment (SOLAR). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01285401 . Accessed 01 Dec 2014"},{"key":"7740_CR25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1745-6215-13-15","volume":"13","author":"J Dorr","year":"2012","unstructured":"Dorr J, Ohlraun S, Skarabis H, Paul F (2012) Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials 13:15","journal-title":"Trials"},{"key":"7740_CR26","unstructured":"Hutchinson M (2012) Dose-related Effects of vitamin D3 on immune responses in patients with clinically isolated syndrome (CISAVID). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01728922 . Accessed 01 Dec 2014"},{"key":"7740_CR27","unstructured":"Carroll W (2013) Preventing the risk of multiple sclerosis using vitamin D in patients with a first demyelinating event in Australia and New Zealand (PrevANZ). http:\/\/www.msra.org.au\/prevanz . Accessed 01 Dec 2014"},{"key":"7740_CR28","unstructured":"Thouvennot E (2013) Efficacy of cholecalciferol (vitamin D3) for delaying the diagnosis of MS after a clinically isolated syndrome (D-Lay-MS). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01817166?term=vitamin+d+clinically+isolated+syndrome&rank=22014 . Accessed 01 Dec 2014"},{"issue":"10","key":"7740_CR29","doi-asserted-by":"crossref","first-page":"e77163","DOI":"10.1371\/journal.pone.0077163","volume":"8","author":"S Modvig","year":"2013","unstructured":"Modvig S, Degn M, Horwitz H, Cramer SP et al (2013) Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS One 8(10):e77163. doi: 10.1371\/journal.pone.0077163","journal-title":"PLoS One"},{"key":"7740_CR30","doi-asserted-by":"crossref","first-page":"582S","DOI":"10.1093\/ajcn\/88.2.582S","volume":"88","author":"G Jones","year":"2008","unstructured":"Jones G (2008) Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 88:582S\u2013586S","journal-title":"Am J Clin Nutr"},{"key":"7740_CR31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00415-006-0315-8","volume":"254","author":"IA Mei van der","year":"2007","unstructured":"van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Taylor BV, Kilpatrick T, Butzkueven H, McMichael AJ (2007) Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 254:581\u2013590","journal-title":"J Neurol"},{"key":"7740_CR32","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1001\/jama.296.23.2832","volume":"296","author":"KL Munger","year":"2006","unstructured":"Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296:2832\u20132838","journal-title":"JAMA"},{"key":"7740_CR33","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3945\/ajcn.112.054502","volume":"97","author":"MC Sachs","year":"2013","unstructured":"Sachs MC, Shoben A, Levin GP, Robinson-Cohen C, Hoofnagle AN, Swords-Jenny N, Ix JH, Budoff M, Lutsey PL, Siscovick DS, Kestenbaum B, de Boer IH (2013) Estimating mean annual 25-hydroxyvitamin D concentrations from single measurements: the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr 97:1243\u20131251","journal-title":"Am J Clin Nutr"},{"key":"7740_CR34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-510X(00)00501-3","volume":"184","author":"H Reiber","year":"2001","unstructured":"Reiber H, Peter JB (2001) Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci 184:101\u2013122","journal-title":"J Neurol Sci"},{"key":"7740_CR35","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/sim.4780141510","volume":"14","author":"KR Hess","year":"1995","unstructured":"Hess KR (1995) Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 14:1707\u20131723","journal-title":"Stat Med"},{"key":"7740_CR36","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1210\/jc.2012-1176","volume":"97","author":"D Durup","year":"2012","unstructured":"Durup D, Jorgensen HL, Christensen J, Schwarz P, Heegaard AM, Lind B (2012) A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab 97:2644\u20132652","journal-title":"J Clin Endocrinol Metab"},{"key":"7740_CR37","doi-asserted-by":"crossref","unstructured":"Durup D, Jorgensen HL, Christensen J, Tjonneland A, Olsen A, Halkjaer J, Lind B, Heegaard AM, Schwarz P (2015) A reverse J-shaped association between serum 25-hydroxyvitamin D and cardiovascular disease mortality\u2014the CopD-study. J Clin Endocrinol Metab (jc20144551) [Epub ahead of print]","DOI":"10.1210\/jc.2014-4551"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-015-7740-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-015-7740-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-015-7740-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T17:59:22Z","timestamp":1717869562000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-015-7740-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,1]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["7740"],"URL":"https:\/\/doi.org\/10.1007\/s00415-015-7740-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,1]]}}}